Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29634435 | 1.00 | CSF1R (1.00) | CSF1RMAPTFLT3MEN1PDGFRB | |
| SCHEMBL6996466 | 0.77 | KMT2A (0.61) | CSF1RMAPTFLT3MEN1PDGFRB | |
| SCHEMBL11127257 | 0.76 | MAPT (0.61) | CSF1RMAPTFLT3MEN1PDGFRB | |
| SCHEMBL13102148 | 0.75 | MEN1 (0.60) | CSF1RMAPTFLT3MEN1PDGFRB | |
| SCHEMBL20670037 | 0.74 | MAPT (0.57) | CSF1RMAPTFLT3MEN1PDGFRB | |
| SCHEMBL18122029 | 0.68 | ALDH1A1 (0.55) | CSF1RMAPTFLT3MEN1PDGFRB | |
| SCHEMBL24796192 | 0.68 | MAPT (0.51) | CSF1RMAPTFLT3MEN1PDGFRB | |
| SCHEMBL18774623 | 0.68 | ERCC5 (0.56) | CSF1RMAPTFLT3MEN1PDGFRB | |
| SCHEMBL18121538 | 0.67 | ALDH1A1 (0.53) | CSF1RMAPTFLT3MEN1PDGFRB | |
| SCHEMBL17306394 | 0.67 | ALDH1A1 (0.53) | CSF1RMAPTFLT3MEN1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1127051-A2 | TRICYCLIC PYRAZOLE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2001-08-29 | — | — | EP | claimed |
| WO-2000027822-A2 | TRICYCLIC PYRAZOLE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-18 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| EP-1778224-B1 | FLT3 INHIBITORS FOR IMMUNE SUPPRESSION | UNIV JOHNS HOPKINS (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20110262465-A1 | PROSTATE STEM CELLS AND USES THEREOF | GENENTECH, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7960392-B2 | Nitrogen-containing heterocyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7960392-B2 | Nitrogen-containing heterocyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-14 | — | — | US | disclosed |
| EP-2314587-A1 | NITROGENATED HETEROCYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20100029690-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-04 | — | — | US | disclosed |
| WO-2010007943-A1 | NITROGENATED HETEROCYCLIC COMPOUND | 旭化成ファーマ株式会社 (JP) | 2010-01-21 | — | — | WO | disclosed |
| US-20090054358-A1 | Flt3 inhibitors for immune suppression | THE JOHN HOPKINS UNIVERSITY (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054358-A1 | Flt3 inhibitors for immune suppression | THE JOHN HOPKINS UNIVERSITY (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1289525-A2 | TRICYCLIC PYRAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Abbott GmbH & Co. KG (DE) | 2003-03-12 | — | — | EP | disclosed |
| US-6462036-B1 | INHIBITING SIGNAL TRANSDUCTION BY MODULATING ACTIVITY OF RECEPTOR AND NONRECEPTOR TYROSINE AND SERINE/THREONINE KINASES TO REGULATE AND MODULATE ABNORMAL OR INAPPROPRIATE CELL PROLIFERATION, DIFFERENTIATION, OR METABOLISM | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-08 | — | — | US | disclosed |
| WO-2001087846-A2 | TRICYCLIC PYRAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) | 2001-11-22 | — | — | WO | disclosed |
| EP-1127051-A2 | TRICYCLIC PYRAZOLE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000027822-A2 | TRICYCLIC PYRAZOLE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054358-A1 | Flt3 inhibitors for immune suppression | FLT3, CSF1R, CSF3R | CSF1R 2/4885MAPT 4122/4885FLT3 1/4885 |
| US-20100029690-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | PTGER1, PTGS1, PTGER2 | CSF1R 1219/4885MAPT 4120/4885FLT3 4700/4885 |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | MDM2, CRBN, FLT3 | CSF1R 806/4885MAPT 3071/4885FLT3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.